logo    Company Page

Changed Risks for PFIZER INC (PFE)

Here are risks that changed year over year. risks from the recent filings of PFIZER INC. Our algorithms work hard to highlight risks unique to this company.
Financial Report; our plans for increasing investment in the US set forth in the Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Strategy––Capital Allocation and Expense Management––Increasing Investment in the US section in our
Derivative Financial Instruments and Hedging Activities
Innovative Health
Item 1A Risk Factors
Eliquis, Xeljanz
Financial Report; the anticipated costs and savings, including from our cost-reduction/productivity initiatives, as well as from our Organizing for Growth initiative, set forth in the
OUTSOURCING
and the
The market value of our common stock may be adversely affected as a result of expected and unexpected costs associated with the proposed transaction and integration of the businesses
We may fail to realize all of the anticipated benefits of the proposed transaction
Basis of Presentation and Significant Accounting Policies
Analysis of the Consolidated Statements of Income
, ––
in this
set forth in the
––
Our Strategy
Selected Product Discussion
Norvasc
The joint venture may be subject to additional risks beyond those associated with Pfizer’s consumer healthcare business
INTERNATIONAL OPERATIONS
Adoption of New Accounting Standards in 2018
Our Financial Guidance for
Financial Report; our anticipated liquidity position set forth in the
Financial Report; the anticipated costs related to our preparations for Brexit set forth in the Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment––The Global Economic Environment section in our
Financial Instruments
––Benefit Plans
BIOLOGIC PRODUCTS
MARKET FLUCTUATIONS IN OUR EQUITY INVESTMENTS
2019
Financial Report and in the Notes to Consolidated Financial Statements—
Form 10-K and in the
Note 7
, and
Form 10-K; the anticipated progress in remediation efforts at certain of our Hospira manufacturing facilities and the expectations related to our supply issues set forth in the
Legal Proceedings
Financial Report; the benefits expected from the reorganization of our commercial operations into three businesses effective at the beginning of our 2019 fiscal year and our expectations regarding growth set forth in the
section and in the Notes to Consolidated Financial Statements—
Our Business Development Initiatives
Contractual Obligations
US HEALTHCARE REFORM
Chantix/Champix, Sutent
and ––
Consumer Healthcare Joint Venture with GSK
Government Regulation and Price Constraints
Selected Measures of Liquidity and Capital Resources
Contingencies and Certain Commitments
Financial Report; and the contributions that we expect to make from our general assets to the Company’s pension, postretirement and deferred compensation plans during
LIBOR
; the benefits expected from our business development transactions; the planned capital spending set forth in the
Note 11
Revenues
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
Costs and Expenses
Note 17
sections in our
Note 3
Note 1
Pension and Postretirement Benefit Plans and Defined Contribution Plans
The required shareholder and regulatory approvals may not be obtained or the regulatory approvals may contain materially burdensome conditions that could have an adverse effect on us or the joint venture or the other conditions to the completion of the proposed transaction may not be satisfied in a timely manner or at all
sections in this
in our
Financial Report; the expected timing of completion and benefits of our proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture set forth in the Item 1 Business––
CONSUMER HEALTHCARE JOINT VENTURE WITH GSK
Organizing for Growth
Texas v Azar
Pricing and Reimbursement
Benefit Plans
About Pfizer
Financial Report; the financial guidance set forth in the
Raw Materials
In the United States
Regulatory Environment/Pricing and Access––US Healthcare Legislation

Debug Info- Version: 2.6